Clozapine: Dangerous orphan or neglected friend?

British Journal of Psychiatry

Volumn 198, Issue 4, 2011, Pages 247-249

  Farooq, Saeed ^a   Taylor, Mark ^b  

^a NATIONAL HEALTH SERVICE   (United Kingdom)

^b NHS LOTHIAN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZOTEPINE;

AGGRESSION; AGRANULOCYTOSIS; BLOOD DYSCRASIA; CARDIOMYOPATHY; CLINICAL PRACTICE; COMORBIDITY; CONSTIPATION; COST UTILITY ANALYSIS; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERSALIVATION; LEUKOPENIA; METABOLIC SYNDROME X; MYOCARDITIS; PHYSICIAN ATTITUDE; QUALITY OF LIFE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEIZURE THRESHOLD; SIDE EFFECT; SUBSTANCE ABUSE; SUICIDAL BEHAVIOR;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; SCHIZOPHRENIA;

EID: 79953700543     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.110.088690     Document Type: Review

References (19)

1. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
2. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009; 166: 152-63.
3. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer H Y, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-10. (Pubitemid 44464569)
4. Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-23. (Pubitemid 44412859)
5. Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukaa T, Ioannidis JPA, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of 2230 patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow up study. BMJ 2006; 333: 224.
6. Krakowski MI, Czobor P, Citrome L, Bark N, Cooper TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2006; 63: 622-9. (Pubitemid 43848293)
7. Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophr Bull 2006; 32: 637.
8. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-7.
9. Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. J Clin Psychiatry 2010; 71: 304-11.
10. Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005; 25: 32-41.
11. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration - New York metropolitan region. Schizophr Bull 2002; 28: 31-42. (Pubitemid 34534748)
12. Tognoni G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Italian Collaborative Study Group on the Outcome of Severe Mental Disorders. Eur J Clin Pharmacol 1999; 55: 685-90.
13. Downs J, Zinkler M. Clozapine: national review of postcode prescribing. Psychiatr Bull 2007; 31: 384-7. (Pubitemid 47565022)
14. National Collaborating Centre for Mental Health. Schizophrenia: Core Interventions in the Treatment of Schizophrenia in Adults in Primary and Secondary Care (Updated Edition) (NICE Clinical Guideline CG82). National Institute for Health and Clinical Excellence, 2009.
15. Wheeler AJ. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother 2008; 42: 852-60. (Pubitemid 351778093)
16. Taylor DM, Young C, Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30-4. (Pubitemid 36182226)
17. Agid O, Remington G, Kapur S, Arenovich T, Zipursky R. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharm 2007; 27: 369-73. (Pubitemid 47075508)
18. Taylor D, Shapland L, Laverick G, Bond J, Munro J. Clozapine - a survey of patient perceptions. Psychiatr Bull 2000; 24: 450-2. (Pubitemid 32011030)
19. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J Psychopharmacology 2010; 24: 965-71.